OUP user menu

Journal of Crohn's and Colitis: 10 (10)


Laurence J. Egan, Ireland

Associate Editors

Shomron Ben-Horin, IsraelSilvio Danese, ItalyPeter Lakatos, HungaryMiles Parkes, UKJesús Rivera-Nieves, USABritta Siegmund, GermanyGijs van den Brink, NLSéverine Vermeire, Belgium


Published on behalf of

What changes in inflammatory bowel disease management can be implemented today?

Edouard Louis, Daniel C. Baumgart, Subrata Ghosh, Fernando Gomollón, Stephen Hanauer, Ailsa Hart, Peter Irving
DOI: http://dx.doi.org/10.1016/S1873-9946(12)60506-6 S260-S267 First published online: 1 February 2012


Innovative ideas are required to improve the management of inflammatory bowel disease and to share best practice that can be implemented into clinical practice today. The use of biomarkers such as calprotectin to monitor disease progression and treatment response could help to improve management of inflammatory bowel disease, but several strategies need to be implemented to make this a reality in clinical practice. The use of calprotectin as a biomarker and the manipulation of the thiopurine pathway to extend the use of current therapies are examples of how basic research can translate into patient benefit. Translational research into the use of microbiota and predictive factors for response and toxicity to drugs, may provide future clinical applications. Global improvement in care in inflammatory bowel disease could also be advanced by improving service provision. For example, the establishment of ‘Centres of Excellence’, a global interactive inflammatory disease map, and the alignment of processes and standards of care within treatment centres may help to achieve better outcomes for patients with inflammatory bowel disease. Realization of this goal, as well as a better understanding of the aetiology of the disease, may be furthered by collaborative efforts between organizations involved in inflammatory bowel disease as well as wider collaboration across countries and globally.

  • Biomarkers
  • Calprotectin
  • Crohn's disease
  • Inflammatory bowel disease
  • Translational research
  • Ulcerative colitis
  • CD
  • Crohn's disease
  • CDAI
  • Crohn's disease activity index
  • Crohn's disease endoscopic index of severity
  • CRP
  • C-reactive protein
  • IBD
  • inflammatory bowel disease
  • QoL
  • quality of life
  • TNF
  • tumour necrosis factor
  • TPMT
  • thiopurine methyltransferase
  • UC
  • ulcerative colitis